Hormone receptor status-Positive (ER and/or PR) Posts on Medivizor
Navigation Menu

Hormone receptor status-Positive (ER and/or PR) Posts on Medivizor

Joint pain and falls among women with breast cancer on aromatase inhibitors.

Posted by on Jan 18, 2019 in Breast cancer | 0 comments

In a nutshell This study wanted to find out if joint pain is associated with falling down in patients with breast cancer who were treated with aromatase inhibitors. The study found that the patients who reported having joint pain were more likely to have a fall than those who had no joint pain. Some background Aromatase inhibitors are medications...

Read More

Adding everolimus to endocrine therapy in patients with HER2- ER+ advanced breast cancer

Posted by on Jan 5, 2019 in Breast cancer | 0 comments

In a nutshell This study wanted to find out if treating breast cancer with everolimus (Afintor) and endocrine therapy is better than only treating with endocrine therapy. The study found that using everolimus in addition to endocrine therapy had a significant benefit to survival in these patients. Some background Breast cancer is classified into types...

Read More

Joint pain management in obese breast cancer patients treated with aromatase inhibitors

Posted by on Dec 8, 2018 in Breast cancer | 0 comments

In a nutshell This article investigated the safety and effectiveness of adding Omega-3 fatty acid (O3-FA) to the management of joint pain in patients with breast cancer treated with aromatase inhibitors. The authors concluded that the addition of O3-FA is safe and gave the greatest benefit to patients who were obese.  Some background...

Read More

Palbociclib and Fulvestrant in Advanced Breast Cancer.

Posted by on Nov 3, 2018 in Breast cancer | 0 comments

In a nutshell This study investigated the overall survival rates of people with breast cancer who were treated with either palbociclib (Ibrance) plus fulvestrant (Faslodex), or just fulvestrant. The study found that the patients who received both palbociclib and fulvestrant had a longer overall survival compared to the group who only received...

Read More

10 years of treatment vs 5 years of treatment with hormone therapy in patients with early stage breast cancer.

Posted by on Oct 22, 2018 in Breast cancer | 0 comments

In a nutshell This study wanted to find out if continuing hormone therapy for 10 years was more effective than doing it for 5 years in patients with early stage breast cancer. The study found that the patients who continued treatment for 10 years survived for longer without the disease coming back compared to those who were only treated for 5...

Read More

Using palbociclib alone or with other therapies in advanced ER+ breast cancer

Posted by on Jul 3, 2018 in Breast cancer | 0 comments

In a nutshell This study aimed to find out if the breast cancer treatment palbociclib (Ibrance) works better alone, or in combination with other endocrine therapies (drugs which act on hormone receptors) used to treat estrogen receptor positive (ER+ – a hormone receptor found on the tumor) breast cancer. The authors found that treating women...

Read More

Endocrine therapy used with targeted therapy is associated with similar quality of life in comparison to endocrine therapy used alone.

Posted by on Feb 12, 2018 in Breast cancer | 0 comments

In a nutshell This study aimed to find out if endocrine therapy (ET) is best used alone or with targeted therapy in the treatment of hormone positive, HER2 negative advanced breast cancer. The study found that patients who used ET and targeted therapy together experienced a better quality of life in some regards compared to ET used alone.  Some...

Read More

The optimal duration of hormone therapy for post menopausal patients with early breast cancer

Posted by on Jan 15, 2018 in Breast cancer | 0 comments

In a nutshell This study aimed to compare the benefits of taking letrozole for 2.5 years versus 5 years in post-menopausal patients with early stage breast cancer. This study found no benefit of five years extended therapy with letrozole compared to 2.5 years, after an initial five years of hormone therapy.  Some background Breast...

Read More

Endocrine therapy and targeted therapy are safe for patients over 65 with HR+/HER2- advanced breast cancer

Posted by on Dec 30, 2017 in Breast cancer | 0 comments

In a nutshell This study aimed to evaluate the effectiveness and safety of endocrine therapy, with or without targeted therapy, for patients with advanced metastatic breast cancer. This study concluded that the use of endocrine therapy and targeted therapy is safe for use in patients over 65.  Some background There are several treatment...

Read More